Gilead Sciences, Inc. $GILD Shares Bought by Wealth Enhancement Advisory Services LLC

Key Points

• Wealth Enhancement Advisory Services LLC increased its position in Gilead Sciences, Inc. by 65.2% in Q2, owning 484,018 shares worth approximately $54 million.
• CEO Daniel Patrick O'Day sold 10,000 shares for $1.14 million, reducing his stake by 1.65% while maintaining 595,725 shares valued at about $67.7 million.
• Gilead recently declared a quarterly dividend of $0.79 payable on September 29, representing an annualized yield of 2.8%.

Wealth Enhancement Advisory Services LLC raised its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 65.2% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 484,018 shares of the biopharmaceutical company's stock after purchasing an additional 191,052 shares during the period. Wealth Enhancement Advisory Services LLC's holdings in Gilead Sciences were worth $54,089,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently modified their holdings of GILD. Brighton Jones LLC lifted its holdings in Gilead Sciences by 20.6% during the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company's stock worth $1,326,000 after buying an additional 2,450 shares during the period. Bison Wealth LLC purchased a new stake in Gilead Sciences during the fourth quarter worth $215,000. Waverly Advisors LLC lifted its holdings in Gilead Sciences by 8.6% during the fourth quarter. Waverly Advisors LLC now owns 29,181 shares of the biopharmaceutical company's stock worth $2,695,000 after buying an additional 2,320 shares during the period. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp lifted its holdings in shares of Gilead Sciences by 14.7% during the 4th quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 238,404 shares of the biopharmaceutical company's stock valued at $22,021,000 after purchasing an additional 30,529 shares during the last quarter. Finally, Vise Technologies Inc. lifted its holdings in shares of Gilead Sciences by 30.5% during the 4th quarter. Vise Technologies Inc. now owns 26,838 shares of the biopharmaceutical company's stock valued at $2,479,000 after purchasing an additional 6,276 shares during the last quarter. Institutional investors own 83.67% of the company's stock.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, CEO Daniel Patrick O'day sold 10,000 shares of the stock in a transaction that occurred on Thursday, August 28th. The shares were sold at an average price of $113.63, for a total transaction of $1,136,300.00. Following the transaction, the chief executive officer owned 595,725 shares of the company's stock, valued at $67,692,231.75. This trade represents a 1.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $118.53, for a total transaction of $296,325.00. Following the transaction, the chief financial officer directly owned 160,110 shares in the company, valued at approximately $18,977,838.30. This represents a 1.54% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 82,000 shares of company stock worth $9,390,030. Company insiders own 0.27% of the company's stock.

Gilead Sciences Trading Up 0.4%

NASDAQ GILD traded up $0.47 during mid-day trading on Friday, reaching $114.09. 12,580,487 shares of the stock were exchanged, compared to its average volume of 5,841,828. Gilead Sciences, Inc. has a 1-year low of $81.83 and a 1-year high of $121.83. The business's fifty day simple moving average is $114.10 and its 200 day simple moving average is $110.06. The stock has a market capitalization of $141.56 billion, a PE ratio of 22.73, a PEG ratio of 0.77 and a beta of 0.36. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.96 by $0.05. The firm had revenue of $7.08 billion for the quarter, compared to analyst estimates of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. Gilead Sciences's revenue was up 1.4% compared to the same quarter last year. During the same quarter last year, the business earned $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, research analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, September 29th. Shareholders of record on Monday, September 15th will be paid a dividend of $0.79 per share. The ex-dividend date of this dividend is Monday, September 15th. This represents a $3.16 dividend on an annualized basis and a yield of 2.8%. Gilead Sciences's dividend payout ratio (DPR) is currently 62.95%.

Analyst Upgrades and Downgrades

GILD has been the subject of a number of research analyst reports. Royal Bank Of Canada raised their target price on Gilead Sciences from $96.00 to $98.00 and gave the stock a "sector perform" rating in a research note on Friday, August 8th. Daiwa America raised Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, August 19th. Rothschild & Co Redburn raised their target price on Gilead Sciences from $136.00 to $143.00 and gave the company a "buy" rating in a research report on Friday, September 12th. Daiwa Capital Markets upgraded Gilead Sciences from a "neutral" rating to an "outperform" rating and set a $128.00 target price on the stock in a research report on Tuesday, August 19th. Finally, Truist Financial upgraded Gilead Sciences from a "hold" rating to a "buy" rating and lifted their price objective for the stock from $108.00 to $127.00 in a report on Friday, August 8th. Three research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $117.17.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.